_version_ 1784867013635604480
author Kockerols, Camille C.B.
Janssen, Jeroen J.W.M
Blijlevens, Nicole M.A.
Klein, Saskia K.
van Hussen-Daenen, Laura G.M.
van Gorkom, Gwendolyn G.Y.
Smit, Willem M.
van Balen, Peter
Biemond, Bart J.
Cruijsen, Marjan J.
Corsten, Maarten F.
te Boekhorst, Peter A.W.
Koene, Harry R.
van Sluis, Geerte L.
Cornelissen, Jan J.
Westerweel, Peter E.
author_facet Kockerols, Camille C.B.
Janssen, Jeroen J.W.M
Blijlevens, Nicole M.A.
Klein, Saskia K.
van Hussen-Daenen, Laura G.M.
van Gorkom, Gwendolyn G.Y.
Smit, Willem M.
van Balen, Peter
Biemond, Bart J.
Cruijsen, Marjan J.
Corsten, Maarten F.
te Boekhorst, Peter A.W.
Koene, Harry R.
van Sluis, Geerte L.
Cornelissen, Jan J.
Westerweel, Peter E.
author_sort Kockerols, Camille C.B.
collection PubMed
description
format Online
Article
Text
id pubmed-9827157
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-98271572023-01-20 Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population Kockerols, Camille C.B. Janssen, Jeroen J.W.M Blijlevens, Nicole M.A. Klein, Saskia K. van Hussen-Daenen, Laura G.M. van Gorkom, Gwendolyn G.Y. Smit, Willem M. van Balen, Peter Biemond, Bart J. Cruijsen, Marjan J. Corsten, Maarten F. te Boekhorst, Peter A.W. Koene, Harry R. van Sluis, Geerte L. Cornelissen, Jan J. Westerweel, Peter E. Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-09-08 /pmc/articles/PMC9827157/ /pubmed/36073515 http://dx.doi.org/10.3324/haematol.2022.281386 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Letter to the Editor
Kockerols, Camille C.B.
Janssen, Jeroen J.W.M
Blijlevens, Nicole M.A.
Klein, Saskia K.
van Hussen-Daenen, Laura G.M.
van Gorkom, Gwendolyn G.Y.
Smit, Willem M.
van Balen, Peter
Biemond, Bart J.
Cruijsen, Marjan J.
Corsten, Maarten F.
te Boekhorst, Peter A.W.
Koene, Harry R.
van Sluis, Geerte L.
Cornelissen, Jan J.
Westerweel, Peter E.
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
title Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
title_full Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
title_fullStr Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
title_full_unstemmed Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
title_short Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
title_sort treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827157/
https://www.ncbi.nlm.nih.gov/pubmed/36073515
http://dx.doi.org/10.3324/haematol.2022.281386
work_keys_str_mv AT kockerolscamillecb treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT janssenjeroenjwm treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT blijlevensnicolema treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT kleinsaskiak treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT vanhussendaenenlauragm treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT vangorkomgwendolyngy treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT smitwillemm treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT vanbalenpeter treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT biemondbartj treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT cruijsenmarjanj treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT corstenmaartenf treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT teboekhorstpeteraw treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT koeneharryr treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT vansluisgeertel treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT cornelissenjanj treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation
AT westerweelpetere treatmentpatternsandclinicaloutcomesofasciminibinarealworldmultiresistantchronicmyeloidleukemiapatientpopulation